Finance

Lists
BEAM:NASDAQ
Beam Therapeutics Inc
၂၀.၉၀ US$
-၀.၁၉%
(-၀.၀၄၀) 1D
၂၁.၆၆ US$
+၃.၆၅% (+၀.၇၆)
After hours
Closed: နို ၂၀, GMT-၅ ၁၆:၀၀:၀၂  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BEAM...
Open
၂၀.၆၀ US$
High
၂၂.၁၀ US$
Low
၂၀.၅၄ US$
Mkt. cap
၂၁၆.၃၁ ဋေ
Avg. vol.
၂.၁၆ သန်း
Volume
၃.၈၉ သန်း
52-wk high
၃၈.၂၆ US$
52-wk low
၂၀.၃၉ US$
EPS
-၁.၀၀ US$
Beta
၂.၂၃
Shares outstanding
၁၀.၃၅ ကုဋေ
No. of employees
၅၅၇
Open
၂၀.၆၀ US$
High
၂၂.၁၀ US$
Low
၂၀.၅၄ US$
Mkt. cap
၂၁၆.၃၁ ဋေ
Avg. vol.
၂.၁၆ သန်း
Volume
၃.၈၉ သန်း
52-wk high
၃၈.၂၆ US$
52-wk low
၂၀.၃၉ US$
EPS
-၁.၀၀ US$
Beta
၂.၂၃
Shares outstanding
၁၀.၃၅ ကုဋေ
No. of employees
၅၅၇
News stories
From web sources and news partners
The Motley Fool
The Motley Fool
·
ပြီးခဲ့သည့် ၁ နာရီ
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
TradingKey
TradingKey
·
ပြီးခဲ့သည့် ၆ နာရီ
S&P 500 Falls Below 200-Day Moving Average: Buy-the-Dip Opportunity or Bear Market Warning?
Beinsure
Beinsure
·
ပြီးခဲ့သည့် ၁၆ နာရီ
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
StoneX
StoneX
·
ပြီးခဲ့သည့် ၂ ရက်
S&P 500, Nasdaq 100 Drive into Correction Territory
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc
CEOJohn Evans
Employees၅၅၇
Founded၂၀၁၇
Headquarters-
SectorHealth Care
Industry-
Websitebeamtx.com
Analyst ratings
Based on 14 analysts giving stock ratings to BEAM in the past 3 months
Strong buy
Buy
12
Hold
2
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for BEAM in the last 3 months.
Highest
Current ၂၀.၉၀ US$
၈၀.၀၀ US$ (+၂၈၂.၇၈%)
Average
၄၉.၃၁ US$ (+၁၃၅.၉၃%)
Lowest
၂၆.၀၀ US$ (+၂၄.၄၀%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Reiterated
၇၈.၀၀ US$
+၂၇၃.၂%
11/11/2026
Samantha Semenkow
Citi
Buy
Reiterated
၆၈.၀၀ US$
+၂၂၅.၄%
11/10/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
၈၀.၀၀ US$
+၂၈၂.၈%
11/11/2026
David Nierengarten
Wedbush
Buy
Maintained
၃၃.၀၀ US$
+၅၇.၉%
11/10/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
၅၁.၀၀ US$
+၁၄၄%
11/05/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
၇၀.၀၀ US$
+၂၃၄.၉%
11/04/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
၇၀.၀၀ US$
+၂၃၄.၉%
11/04/2026
Luca Issi
RBC Capital
Hold
Reiterated
၂၆.၀၀ US$
+၂၄.၄%
11/03/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
၄၁.၀၀ US$
+၉၆.၂%
11/04/2026
Maury Raycroft
Jefferies
Buy
Maintained
၄၉.၀၀ US$
+၁၃၄.၄%
11/03/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
၄၅.၀၀ US$
+၁၁၅.၃%
10/28/2026
Unknown Analyst
UBS
Hold
Maintained
၂၈.၀၀ US$
+၃၄%
10/28/2026
Unknown Analyst
Wedbush
Buy
Maintained
၆၅.၀၀ US$
+၂၁၁%
10/14/2026
Boris Peaker
JonesTrading
Buy
Reiterated
၃၅.၀၀ US$
+၆၇.၅%
09/09/2026
Mara Goldstein
Clear Street
Buy
Reiterated
၃၇.၀၀ US$
+၇၇%
09/09/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
09/08/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
၄၄.၀၀ US$
+၁၁၀.၅%
08/06/2026
William Maughan
Clear Street
Buy
Maintained
၃၇.၀၀ US$
+၇၇%
08/05/2026
William Pickering
Bernstein
Buy
Reiterated
၃၉.၀၀ US$
+၈၆.၆%
05/13/2026
Soumit Roy
JonesTrading
Buy
Maintained
၃၅.၀၀ US$
+၆၇.၅%
04/06/2026
Last report
၂၀၂၆ နို ၃
Fiscal period
Q3 2026
-၁.၂၈ US$ / -၁.၁၇ US$
-၉.၃၇%miss
Revenue / Est. (USD)
၃.၀၇ သိန်း / ၉.၉၆ သန်း
-၉၆.၉၂%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
၁၁.၄၁ ကုဋေ
၃.၁၇ ကုဋေ
၄.၉၀ သိန်း
၃.၀၇ သိန်း
Cost of goods sold
၉.၉၃ ကုဋေ
၁၀.၄၅ ကုဋေ
၉.၅၁ ကုဋေ
၁၁.၀၁ ကုဋေ
Cost of revenue
၉.၉၃ ကုဋေ
၁၀.၄၅ ကုဋေ
၉.၅၁ ကုဋေ
၁၁.၀၁ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၃.၂၃ ကုဋေ
၃.၄၄ ကုဋေ
၃.၁၉ ကုဋေ
၃.၁၅ ကုဋေ
Operating expense
၃.၂၃ ကုဋေ
၃.၄၄ ကုဋေ
၃.၁၉ ကုဋေ
၃.၁၅ ကုဋေ
Total operating expenses
၁၃.၁၆ ကုဋေ
၁၃.၉၀ ကုဋေ
၁၂.၇၀ ကုဋေ
၁၄.၁၆ ကုဋေ
Operating income
-၁.၇၄ ကုဋေ
-၁၀.၇၂ ကုဋေ
-၁၂.၆၆ ကုဋေ
-၁၄.၁၃ ကုဋေ
Other non operating income
၅.၀၀ သောင်း
၂.၅၀ သန်း
-၄.၂၀ သန်း
၄.၇၀ သန်း
EBT including unusual items
၂၄.၄၃ ကုဋေ
-၉.၄၃ ကုဋေ
-၁၂.၂၇ ကုဋေ
-၁၃.၄၄ ကုဋေ
EBT excluding unusual items
-၆.၇၆ သန်း
-၉.၄၈ ကုဋေ
-၁၂.၃၃ ကုဋေ
-၁၃.၀၅ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
၂၄.၄၃ ကုဋေ
-၉.၄၃ ကုဋေ
-၁၂.၂၇ ကုဋေ
-၁၃.၄၄ ကုဋေ
Net profit margin
၂၁၄.၀၉%
-၂၉၇.၁၈%
-၂၅,၀၃၆.၃၃%
-၄၃,၇၈၀.၁၃%
Earnings per share
၂.၃၃
-၀.၉၁
-၁.၁၈
-၁.၂၈
Interest and investment income
၁.၀၆ ကုဋေ
၉.၈၇ သန်း
၁.၀၂ ကုဋေ
၈.၈၂ သန်း
Interest expense
-
-
-၂.၆၇ သန်း
-၂.၇၂ သန်း
Net interest expenses
၁.၀၆ ကုဋေ
၉.၈၇ သန်း
၇.၄၉ သန်း
၆.၀၉ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၁၈ ကုဋေ
-၁၀.၁၆ ကုဋေ
-၁၂.၁၁ ကုဋေ
-၁၃.၅၉ ကုဋေ
Gain or loss from assets sale
-
-
၄.၄၀ သောင်း
-၁.၀၀ ထောင်
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ